ME02602B - Antikoagulantni protivotrovi - Google Patents
Antikoagulantni protivotroviInfo
- Publication number
- ME02602B ME02602B MEP-2017-29A MEP2917A ME02602B ME 02602 B ME02602 B ME 02602B ME P2917 A MEP2917 A ME P2917A ME 02602 B ME02602 B ME 02602B
- Authority
- ME
- Montenegro
- Prior art keywords
- dabigatran
- antibody
- seq
- patient
- acylglucuronide
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39583—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials not provided for elsewhere, e.g. haptens, coenzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/626—Diabody or triabody
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/10—Screening for compounds of potential therapeutic value involving cells
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Urology & Nephrology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Diabetes (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Mycology (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Toxicology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Claims (20)
1.Molekul antitela koji ima vezujuće sposobnosti za dabigatran koji sadrži varijabilni domen teškog lanca sa CDR1 SEQ ID NO: 1, CDR2 SEQ ID NO: 7, CDR3 SEQ ID NO: 10, i varijabilni domen lakog lanca sa CDR1 SEQ ID NO: 13, CDR2 SEQ ID NO: 14, i CDR3 SEQ ID NO: 15.
2. Molekul antitela prema zahtevu 1 koji sadrži varijabilni domen teškog lanca SEQ ID NO: 24, i varijabilni domen lakog lanca SEQ ID No: 27.
3. Molekul antitela prema bilo kom od prethodnih zahteva koji je monoklonalno antitelo, ljudsko antitelo, humanizovano antitelo, himerno antitelo, fragment antitela, prvenstveno Fab, Fab’, ili F(ab’)2 fragment, antitelo pojedinačnog lanca, prvesntveno varijabilni fragment pojedinačnog lanca (scFv), Mali Modularni Imunofarmaceutski (Small Modular Immunopharmaceutical (SMIP)), ili diatelo.
4. Molekul antitela prema zahtevu 3 koji je scFv, pri čemu varijabilni domen teškog lanca i varijabilni domen lakog lanca su povezani jedan za drugi preko vezujućeg peptida odabranog između grupe koja se sastoji od SEQ ID NO: 28, SEQ ID NO: 29, SEQ ID NO: 30, i SEQ ID NO: 31.
5. Molekul antitela prema zahtevu 3 koji ima teški lanac koji sadrži SEQ ID NO: 40, i laki lanac koji sadrži SEQ ID NO: 35.
6. Antitelo prema zahtevu 3 koje je Fab molekul koji ima Fd fragment koji sadrži SEQ ID NO: 36, ili SEQ ID NO: 41, i laki lanac koji sadrži SEQ ID NO: 37.
7. Antitelo prema zahtevu 6 koje ima Fd fragment koji sadrži SEQ ID NO: 36, i laki lanac koji sadrži SEQ ID NO: 37.
8. Molekul antitela prema bilo kom od prethodnih zahteva za korišćenje kao medikament.
9. Molekul antitela prema bilo kom od prethodnih zahteva za korišćenje kao protivotrov dabigatran ili dabigatran eteksilat terapije, i/ili za preokret prekomerne doze dabigatrana ili dabigatran eteksilata.
10. Postupak proizvodnje molekula antitela prema bilo kom od prethodnih zahteva, koji sadrži (a) obezbeđivanje ćelije domaćina koja sadrži jednu ili više nukleinskih kiselina koje kodiraju navedeni molekul antitela u funkcionalnoj vezi sa ekspresionom kontrolnom sekvencom, (b) kultivisanje navedene ćelije domaćina, i (c) oporavak molekula antitela iz ćelijske kulture.
11. Kit sadrži: (a)antitelo prema bilo kom od zahteva 1 do 7, ili njegovu farmaceutsku kompoziciju; (b)farmaceutsku kompoziciju dabigatrana, dabigatran eteksilata, proleka dabigatrana ili njegovu farmaceutski prihvatljivu so; (c)posudu; i (d)etiketu.
12. Kit prema zahtevu 11, pri čemu farmaceutski prihvatljiva so dabigatran eteksilata je mezilatna so.
13. Kit prema zahtevu 11 ili 12, pri čemu jačina po doznoj jedinici dabigatrana, dabigatran eteksilata, proleka dabigatrana ili njegove farmaceutski prihvatljive soli je između 75 mg i 300 mg, ili jednom na dan (QD) ili dva puta na dan (BID).
14. Kit obuhvata: (a) prvu farmaceutsku kompoziciju koja sadrži dabigatran, dabigatran eteksilat, prolek dabigatrana ili njegova farmaceutski prihvatljiva so; (b) drugu farmaceutsku kompoziciju koja sadrži antitelo prema bilo kom od zahteva 1 do 7; (c) instrukcije za odvojenu primenu navedenih prvih i drugih farmaceutskih kompozicija na pacijenta, pri čemu su navedena prve i druge farmaceutske kompozicije sadržane u odvojenim posudama i navedena druga farmaceutska kompozicija je za korišćenje u primeni na pacijenta kome je potrebna neutralizacija ili delimična nautralizacija dabigatrana ili 1-O-acilglukuronid dabigatrana.
15. Antitelo prema bilo kom od zahteva 1 do 7 za korišćenje u postupku neutralizacije ili delimične neutralizacije dabigatrana ili 1- O-acilglukuronid dabigatrana kod pacijenta koji se leči sa dabigatranom, dabigatran eteksilatom, prolekom dabigatrana ili njegovom farmaceutski prihvatljivom soli.
16. Antitelo prema bilo kom od zahteva 1 do 7 za korišćenje u postupku neutralizacije ili delimične nautralizacije dabigatrana ili 1- O-acilglukuronid dabigatrana kod pacijenta obuhvata: (a) potvrdu da je pacijent lečen sa dabigatranom, dabigatran eteksilatom, prolekom dabigatrana ili njegovom farmaceutski prihvatljivom soli, i količinom koja je uzeta od strane pacijenta; (b) neutralizaciju dabigatrana ili 1-O-acilglukuronida sa antitelom prema bilo kom od zahteva 1 do 9 pre izvođenja testa ili analize zgrušavanja ili koagulacije gde će se dabigatran ili 1-O-acilglukuronid dabigatrana ometati tačno očitavanje rezultata testa ili analize; (c) izvođenje testa ili analize zgrušavanja ili koagulacije na uzorku uzetom od pacijenta kako bi se utvrdio nivo obrazovanja ugruška bez prisustva dabigatrana ili 1-O-acilglukuronid dabigatrana; i (d) podešavanje količine dabigatrana, dabigatran eteksilata, proleka dabigatrana ili njegove farmaceutski prihvatljive soli primenjene na pacijenta u cilju da se postigne odgovarajući balans između obrazovanja ugruška i degradacije kod pacijenta.
17. Antitelo za korišćenje prema zahtevima 15 ili 16, pri čemu količina antitela prema dabigatranu ili 1-O-acilglukuronid dabigatranu je u molarnom odnosu između 0.1 i 100.
18. Antitelo za korišćenje prema zahtevu 17, pri čemu količina antitela prema dabigatranu ili 1-O-acilglukuronid dabigatranu je u molarnom odnosu između 0.1 i 10.
19. Antitelo za korišćenje prema zahtevu 16, pri čemu tačno očitani rezultat testa ili analize je tačno očitani nivoi fibrinogena, aktivirane rezistentnosti proteina C, ili srodni testovi.
20. Farmaceutska kompozicija koja sadrži antitelo prema jednom ili više zahteva 1 do 7, i farmaceutski prihvatljivi nosač.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10151239 | 2010-01-20 | ||
| US38391410P | 2010-09-17 | 2010-09-17 | |
| PCT/EP2011/050749 WO2011089183A2 (en) | 2010-01-20 | 2011-01-20 | Anticoagulant antidotes |
| EP11703410.8A EP2525812B1 (en) | 2010-01-20 | 2011-01-20 | Anticoagulant antidotes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ME02602B true ME02602B (me) | 2017-06-20 |
Family
ID=42061991
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-2017-29A ME02602B (me) | 2010-01-20 | 2011-01-20 | Antikoagulantni protivotrovi |
Country Status (43)
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR079944A1 (es) * | 2010-01-20 | 2012-02-29 | Boehringer Ingelheim Int | Anticuerpo neutralizante de la actividad de un anticoagulante |
| EP3252076B1 (en) | 2011-01-14 | 2019-09-04 | The Regents Of The University Of California | Diagnostic use of antibodies against ror-1 protein |
| JP2014506448A (ja) * | 2011-01-19 | 2014-03-17 | バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | 凝固因子の阻害剤に対する結合タンパク質 |
| WO2012130834A1 (en) * | 2011-03-30 | 2012-10-04 | Boehringer Ingelheim International Gmbh | Anticoagulant antidotes |
| CN104080772B (zh) | 2011-11-29 | 2016-10-05 | 佩罗斯菲尔股份有限公司 | 抗凝血逆转剂 |
| PE20160533A1 (es) | 2013-03-14 | 2016-06-09 | Bayer Healthcare Llc | Anticuerpos monoclonales contra antitrombina beta que forma complejos con heparina |
| JP2016539926A (ja) * | 2013-10-25 | 2016-12-22 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 抗凝血薬の解毒剤 |
| TW201623331A (zh) * | 2014-03-12 | 2016-07-01 | 普羅帝納生物科學公司 | 抗黑色素瘤細胞黏著分子（ｍｃａｍ）抗體類及使用彼等之相關方法 |
| CN105223348A (zh) * | 2014-05-26 | 2016-01-06 | 北京九强生物技术股份有限公司 | 人抗凝血酶iii的胶乳增强免疫比浊法检测试剂盒 |
| EP2980218A1 (en) | 2014-07-30 | 2016-02-03 | Rheinische Friedrich-Wilhelms-Universität Bonn | Aptamer thrombin complex for use as an antidote to direct acting thrombin inhibitors |
| WO2016019145A1 (en) * | 2014-07-31 | 2016-02-04 | Haemonetics Corporation | Detection and classification of an anticoagulant using a clotting assay |
| WO2016044645A1 (en) * | 2014-09-17 | 2016-03-24 | Elmaleh David R | Anticoagulant derivatives for cardiovascular imaging |
| EP4205743A1 (en) | 2014-12-31 | 2023-07-05 | Shenzhen Pharmacin Co., Ltd. | Pharmaceutical composition and preparation method therefor |
| US10449195B2 (en) | 2016-03-29 | 2019-10-22 | Shenzhen Pharmacin Co., Ltd. | Pharmaceutical formulation of palbociclib and a preparation method thereof |
| US11879014B2 (en) | 2017-03-17 | 2024-01-23 | Tusk Therapeutics Ltd. | Method of treating cancer or depleting regulatory T cells in a subject by administering a human IGG1 anti-CD25 antibody |
| WO2019124468A1 (ja) * | 2017-12-24 | 2019-06-27 | ノイルイミューン・バイオテック株式会社 | ヒトメソセリンを特異的に認識する細胞表面分子、ｉｌ－７、及びｃｃｌ１９を発現する免疫担当細胞 |
| US11814434B2 (en) | 2018-03-13 | 2023-11-14 | Tusk Therapeutics Ltd. | Anti-CD25 for tumour specific cell depletion |
| WO2019217705A1 (en) * | 2018-05-11 | 2019-11-14 | Proplex Technologies, LLC | Binding proteins and chimeric antigen receptor t cells targeting gasp-1 granules and uses thereof |
| EP3873916B8 (en) | 2018-10-29 | 2025-03-26 | Shanghai Synergy Pharmaceutical Sciences, Ltd. | Novel dipeptide compounds and uses thereof |
| US12251377B2 (en) | 2019-03-06 | 2025-03-18 | University Of Rochester | Anticoagulant compositions and uses thereof |
| CN114306245A (zh) | 2020-09-29 | 2022-04-12 | 深圳市药欣生物科技有限公司 | 无定形固体分散体的药物组合物及其制备方法 |
| TW202321311A (zh) * | 2021-08-02 | 2023-06-01 | 日商諾伊爾免疫生物科技股份有限公司 | 與scFv等之連接子結合的抗體 |
| US11446286B1 (en) * | 2022-02-28 | 2022-09-20 | King Faisal University | Treatment of fungal infections using dabigatran etexilate |
| NL2036011B1 (en) | 2023-10-12 | 2025-04-30 | Synapse Res Institute | Molecules for reversing anti-coagulant activity of direct oral anticoagulants |
| WO2025149667A1 (en) | 2024-01-12 | 2025-07-17 | Pheon Therapeutics Ltd | Antibody drug conjugates and uses thereof |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6087380A (en) | 1949-11-24 | 2000-07-11 | Boehringer Ingelheim Pharma Kg | Disubstituted bicyclic heterocycles, the preparations and the use thereof as pharmaceutical compositions |
| WO1988001649A1 (en) | 1986-09-02 | 1988-03-10 | Genex Corporation | Single polypeptide chain binding molecules |
| FI903489A0 (fi) | 1988-11-11 | 1990-07-10 | Medical Res Council | Ligander med en enda sektion, receptorer innehaollande naemnda ligander, foerfaranden foer deras framstaellning samt anvaendning av liganderna och receptorerna. |
| US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| JP3490437B2 (ja) * | 1992-01-23 | 2004-01-26 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング | 単量体および二量体抗体フラグメント融合タンパク質 |
| DE4203965A1 (de) | 1992-02-11 | 1993-08-12 | Max Planck Gesellschaft | Antidot fuer hirudin und synthetische thrombininhibitoren |
| EP1498427B1 (en) | 1992-08-21 | 2009-12-16 | Vrije Universiteit Brussel | Immunoglobulins devoid of light chains |
| DK0672142T3 (da) | 1992-12-04 | 2001-06-18 | Medical Res Council | Multivalente og multispecifikke bindingsproteiner samt fremstilling og anvendelse af disse |
| ATE183513T1 (de) | 1993-06-03 | 1999-09-15 | Therapeutic Antibodies Inc | Herstellung von antikörperfragmenten |
| AT404357B (de) | 1995-06-13 | 1998-11-25 | Immuno Ag | Prothrombin-derivate |
| DE19605126A1 (de) | 1996-02-12 | 1997-08-14 | Basf Ag | Thrombinmuteine als Antidot für Thrombininhibitoren |
| US6200955B1 (en) | 1996-06-11 | 2001-03-13 | Commonwealth Biotechnologies, Inc. | Heparin binding peptides |
| GB9625640D0 (en) | 1996-12-10 | 1997-01-29 | Celltech Therapeutics Ltd | Biological products |
| PE121699A1 (es) * | 1997-02-18 | 1999-12-08 | Boehringer Ingelheim Pharma | Heterociclos biciclicos disustituidos como inhibidores de la trombina |
| JP2002505574A (ja) | 1997-04-30 | 2002-02-19 | エンゾン，インコーポレイテッド | ポリアルキレンオキシド修飾された単鎖ポリペプチド |
| DE19729544A1 (de) * | 1997-07-10 | 1999-01-14 | Basf Ag | Ancrod spezifische monoklonale Antikörper, Antikörperfragmente, deren Mischung oder Derivate und deren Verwendung |
| US6440417B1 (en) | 1998-11-06 | 2002-08-27 | Conjuchem, Inc. | Antibodies to argatroban derivatives and their use in therapeutic and diagnostic treatments |
| US6624141B1 (en) | 1999-03-17 | 2003-09-23 | The Regents Of The University Of Michigan | Protamine fragment compositions and methods of use |
| JP2003530838A (ja) | 2000-04-12 | 2003-10-21 | ヒューマン ゲノム サイエンシズ インコーポレイテッド | アルブミン融合タンパク質 |
| CA2433877C (en) | 2001-01-17 | 2014-11-18 | Aptevo Research And Development Llc | Binding domain-immunoglobulin fusion proteins |
| US20040097547A1 (en) | 2001-04-16 | 2004-05-20 | Taveras Arthur G. | 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands |
| US20070031438A1 (en) * | 2001-12-10 | 2007-02-08 | Junghans Richard P | Antibodies as chimeric effector cell receptors against tumor antigens |
| AU2002351896A1 (en) | 2001-12-11 | 2003-06-23 | Ablynx N.V. | Method for displaying loops from immunoglobulin domains in different contexts |
| EP1517921B1 (en) | 2002-06-28 | 2006-06-07 | Domantis Limited | Dual specific ligands with increased serum half-life |
| WO2004041862A2 (en) | 2002-11-08 | 2004-05-21 | Ablynx N.V. | Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor |
| SI1639011T1 (sl) | 2003-06-30 | 2009-04-30 | Domantis Ltd | Pegilirana protitelesa z enojno domeno (dAb) |
| BRPI0816837B1 (pt) * | 2007-09-28 | 2022-10-18 | Portola Pharmaceuticals, Inc | Composições farmacêuticas, polipeptídeo isolado de duas cadeias e uso de uma composição farmacêutica |
| AR070141A1 (es) * | 2008-01-23 | 2010-03-17 | Glenmark Pharmaceuticals Sa | Anticuerpos humanizados especificos para el factor von willebrand |
| AR077909A1 (es) | 2009-08-24 | 2011-09-28 | Boehringer Ingelheim Int | Intervenciones de urgencia de carbon vegetal activo con sobredosificacion con etexilato de dabigatran |
| AR079944A1 (es) | 2010-01-20 | 2012-02-29 | Boehringer Ingelheim Int | Anticuerpo neutralizante de la actividad de un anticoagulante |
-
2011
- 2011-01-19 AR ARP110100179A patent/AR079944A1/es active IP Right Grant
- 2011-01-19 TW TW100102006A patent/TWI513466B/zh active
- 2011-01-20 MY MYPI2012002840A patent/MY162323A/en unknown
- 2011-01-20 AP AP2012006242A patent/AP2012006242A0/xx unknown
- 2011-01-20 PT PT117034108T patent/PT2525812T/pt unknown
- 2011-01-20 UA UAA201209779A patent/UA110470C2/ru unknown
- 2011-01-20 PH PH1/2012/501493A patent/PH12012501493A1/en unknown
- 2011-01-20 SI SI201131156A patent/SI2525812T1/sl unknown
- 2011-01-20 NZ NZ599508A patent/NZ599508A/en unknown
- 2011-01-20 RS RS20170195A patent/RS55683B1/sr unknown
- 2011-01-20 UY UY0001033196A patent/UY33196A/es active IP Right Grant
- 2011-01-20 CA CA2787566A patent/CA2787566A1/en not_active Abandoned
- 2011-01-20 WO PCT/EP2011/050749 patent/WO2011089183A2/en not_active Ceased
- 2011-01-20 PE PE2012000997A patent/PE20121516A1/es active IP Right Grant
- 2011-01-20 PL PL11703410T patent/PL2525812T3/pl unknown
- 2011-01-20 GE GEAP201112836A patent/GEP20156341B/en unknown
- 2011-01-20 MA MA35080A patent/MA33936B1/fr unknown
- 2011-01-20 HU HUE11703410A patent/HUE032263T2/en unknown
- 2011-01-20 MX MX2012008360A patent/MX2012008360A/es active IP Right Grant
- 2011-01-20 HR HRP20170613TT patent/HRP20170613T1/hr unknown
- 2011-01-20 KR KR1020127019086A patent/KR101781787B1/ko active Active
- 2011-01-20 LT LTEP11703410.8T patent/LT2525812T/lt unknown
- 2011-01-20 ES ES11703410.8T patent/ES2614992T3/es active Active
- 2011-01-20 DK DK11703410.8T patent/DK2525812T3/en active
- 2011-01-20 EA EA201201016A patent/EA028371B1/ru active Protection Beyond IP Right Term
- 2011-01-20 JP JP2012549355A patent/JP5575923B2/ja active Active
- 2011-01-20 ME MEP-2017-29A patent/ME02602B/me unknown
- 2011-01-20 AU AU2011208719A patent/AU2011208719C1/en active Active
- 2011-01-20 BR BR112012018021-5A patent/BR112012018021B1/pt active IP Right Grant
- 2011-01-20 SG SG2012052445A patent/SG182552A1/en unknown
- 2011-01-20 CN CN201180006616.4A patent/CN102711813B/zh active Active
- 2011-01-20 EP EP16205771.5A patent/EP3195876A1/en not_active Withdrawn
- 2011-01-20 EP EP11703410.8A patent/EP2525812B1/en active Active
- 2011-01-20 US US13/010,403 patent/US8486398B2/en active Active
-
2012
- 2012-04-19 ZA ZA2012/02876A patent/ZA201202876B/en unknown
- 2012-04-25 IL IL219427A patent/IL219427B/en active IP Right Grant
- 2012-07-18 TN TNP2012000366A patent/TN2012000366A1/en unknown
- 2012-07-23 CO CO12123109A patent/CO6571889A2/es active IP Right Grant
- 2012-08-14 EC ECSP12012105 patent/ECSP12012105A/es unknown
-
2013
- 2013-06-13 US US13/916,994 patent/US9034822B2/en active Active
-
2014
- 2014-07-02 JP JP2014136811A patent/JP2014210794A/ja active Pending
-
2015
- 2015-04-13 US US14/684,576 patent/US20150210778A1/en not_active Abandoned
-
2017
- 2017-03-22 CY CY20171100361T patent/CY1118875T1/el unknown
- 2017-07-06 NL NL300882C patent/NL300882I2/nl unknown
- 2017-07-10 CY CY2017025C patent/CY2017025I2/el unknown
- 2017-07-10 FR FR17C1026C patent/FR17C1026I2/fr active Active
- 2017-07-10 LT LTPA2017021C patent/LTC2525812I2/lt unknown
- 2017-07-11 NO NO2017034C patent/NO2017034I1/no unknown
- 2017-07-12 LU LU00028C patent/LUC00028I2/fr unknown
- 2017-07-13 HU HUS1700030C patent/HUS1700030I1/hu unknown
-
2022
- 2022-08-12 NO NO2022036C patent/NO2022036I1/no unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ME02602B (me) | Antikoagulantni protivotrovi | |
| Huo et al. | A potent SARS-CoV-2 neutralising nanobody shows therapeutic efficacy in the Syrian golden hamster model of COVID-19 | |
| Qian et al. | Lactic acid promotes metastatic niche formation in bone metastasis of colorectal cancer | |
| CN112646038B (zh) | 抗人Trop-2抗体及其应用 | |
| ES2687783T3 (es) | Biomarcadores de cáncer y usos de los mismos | |
| ES2657970T3 (es) | Anticuerpos contra ROR1 de conejo/ser humano quiméricos | |
| CN114044821B (zh) | 一种抗新冠病毒全人源广谱中和抗体zwc12及应用 | |
| CN113735969A (zh) | 一种全人源抗新冠病毒广谱高中和活性单克隆抗体及应用 | |
| HRP20210888T1 (hr) | Vezujuće molekule specifične za cd73 i njihova upotreba | |
| AR079903A1 (es) | Formulacion de anticuerpo y regimenes terapeuticos. envase farmaceutico. kit. | |
| JP2018508462A5 (me) | ||
| RU2013104299A (ru) | Способ идентификации пациента с повышенной вероятностью ответа на противораковую терапию | |
| AR068566A1 (es) | Proteinas fijadoras de antigeno de factor de crecimiento del tipo factor de crecimiento epidermico fijador de heparina | |
| WO2014047624A1 (en) | Anti-ddr1 antibodies | |
| HRP20060033A2 (en) | Human anti-ngf neutralizing antibodies as selective ngf pathway inhibitors | |
| HRP20200882T1 (hr) | Vezujuće molekule specifične za asct2 i njihova uporaba | |
| Sakoda et al. | Enamel matrix derivative induces production of vascular endothelial cell growth factor in human gingival fibroblasts | |
| CN109923129A (zh) | 巨噬细胞刺激蛋白受体（或RON-Recepteur d,Origine Nantais）抗体及其用途 | |
| US20140328850A1 (en) | Apelin antigen-binding proteins and uses thereof | |
| JP2014515740A5 (me) | ||
| Hong et al. | Universal endogenous antibody recruiting nanobodies capable of triggering immune effectors for targeted cancer immunotherapy | |
| CN113735970A (zh) | 一种抗新冠病毒全人源广谱中和抗体及应用 | |
| ME02491B (me) | Proteini koji vezuju antigene specifični za serumsku amiloidnu p komponentu | |
| DE602007009116D1 (de) | Zusammensetzungen und verfahren zur verabreichung anti-aktivierter ras-antikörper an zellen | |
| Wang et al. | Development of an SPR-based binding assay for characterization of anti-CD20 antibodies to CD20 expressed on extracellular vesicles |